Rentschler Biopharma Adds Senior Executive to Growing U.S. Team

February 13, 2020 Rentschler Biopharma Adds Senior Executive to Growing U.S. Team

Grace Kim joins as Vice President Business Development – North America and APAC

Laupheim, Germany and Milford, MA, USA, February 13, 2020 - Rentschler Biopharma SE, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the hiring of Grace Kim as Vice President Business Development - North America and APAC. This is a newly created, U.S.-based position.

Federico Pollano, Senior Vice President Business Development, commented: "We are delighted to have Grace join Rentschler Biopharma. She is a talented leader with proven experience in successfully growing global CDMO businesses who shares our client-centric approach. We, at Rentschler Biopharma, believe that collaborating closely with our strategic partners - our clients - is essential to the successful bioprocess development and production of high-quality complex biopharmaceuticals. Grace will play a key role in expanding our offering of best-in-class services for cell culture projects as well as for new therapeutic modalities. We warmly welcome Grace to our growing U.S.-based team."

Grace Kim is an accomplished business development executive with over 20 years of broad-based experience in the biopharmaceutical industry. She has a proven track record of driving significant growth in revenue through successful execution of long-term partnerships. Grace has held several global business development positions at companies specializing in process development and cGMP production of recombinant protein therapeutics in both microbial and mammalian expression systems. Most recently, she was Vice President at Northway Biotechpharma, Inc. Before that, she held a senior leadership position with the global contract manufacturing organization, Samsung Biologics. Grace has a BA from Hamilton College and an MS from The Johns Hopkins University.

Ms. Kim said: "Rentschler Biopharma has a reputation for high quality, dependability and innovation, and I am excited to join the team as it expands its international footprint to the U.S. as well as Asia Pacific. I look forward to bringing in new strategic partnerships to maximize the utilization of the Milford site as well as to expand the global business development team, commensurate with growth in business."

About Rentschler Biopharma's U.S. site

Rentschler Biopharma acquired its U.S. site, located in Milford, MA in the greater Boston area, in early 2019. The FDA, EMA and Health Canada licensed, 93,000 square foot facility will be qualified as a multi-product site offering clients innovative solutions. The first step in establishing Rentschler Biopharma's center of excellence in North America is a 500 L single-use bioreactor that will be operational by mid-2020. The next steps include another building for large-scale SU manufacturing and lab capacity for new therapeutic modalities. The company plans to leverage its expertise for client projects through every phase, be it early stage development or clinical and commercial production. With its innovative and highly flexible business model, the Milford site is already taking on new projects, including complex and difficult-to-manufacture proteins, such as multispecific antibodies. In total, Rentschler Biopharma expects to invest around $55 million in these expansions and to hire at least 75 additional people at the site to keep pace with the site development and business growth.

Contact Person:
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication
communications@rentschler-biopharma.com